1. Zhai Y, Busuttil RW, Kupiec-Weglinski JW. Liver ischemia and
reperfusion injury: new Insights into mechanisms of innateadaptive immune-mediated tissue inflammation. Am J
Transplant. 2011;11:1563e1569.
2. Fondevila C, Busuttil RW, Kupiec-Weglinski JW. Hepatic
ischemia/reperfusion injuryda fresh look. Exp Mol Pathol.
2003;74:86e93.
3. Selzner N. Protective strategies against ischemic injury of the
liver. Gastroenterology. 2003;125:917e936.
4. Lisman T, Porte RJ. Rebalanced hemostasis in patients with
liver disease: evidence and clinical consequences. Blood.
2010;116:878e885.
5. Kloek J, Heger M, Gaag NVD, et al. Effect of preoperative
biliary drainage on coagulation and fibrinolysis in severe
obstructive cholestasis. J Clin Gastroenterol. 2010;44:646e652.
6. Kassel KM, Owens AP, Rockwell CE, et al. Protease-activated
receptor 1 and hematopoietic cell tissue factor are required
for hepatic steatosis in mice fed a western diet. Ajpa.
2011;179:2278e2289.
7. Owens III AP, Passam FH, Antoniak S, et al. Monocyte tissue
factoredependent activation of coagulation in
hypercholesterolemic mice and monkeys is inhibited by
simvastatin. J Clin Invest. 2012;122:558e568.
8. Coughlin SR. Protease-activated receptors in hemostasis,
thrombosis and vascular biology. J Thromb Haemost.
2005;3:1800e1814.
9. Kassel KM, Sullivan BP, Cui W, Copple BL, Luyendyk JP.
Therapeutic administration of the direct thrombin inhibitor
argatroban reduces hepatic inflammation in mice with
established fatty liver disease. Ajpa. 2012;181:1287e1295.
10. Kopec AK, Joshi N, Towery KL, et al. Thrombin inhibition with
dabigatran protects against high-fat diet-induced fatty liver
disease in mice. J Pharmacol Exp Ther. 2014;351:288e297.
11. Luyendyk JP, Sullivan BP, Guo GL, Wang R. Tissue factordeficiency and protease activated receptor-1-deficiency
reduce inflammation elicited by diet-induced steatohepatitis
in mice. Ajpa. 2010;176:177e186.
12. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning
of a functional thrombin receptor reveals a novel proteolytic
mechanism of receptor activation. Cell. 1991;64:1057e1068.
13. Charles TE. The protein C pathway. Chest. 2003;124:26Se32S.
15
14. McLaughlin JN, Shen L, Holinstat M, Brooks JD, DiBenedetto E,
Hamm HE. Functional selectivity of G protein signaling by
agonist peptides and thrombin for the protease-activated
receptor-1. J Biol Chem. 2005;280:25048e25059.
15. Ossovskaya VS, Bunnett NW. Protease-activated receptors:
contribution to physiology and disease. Physiol Rev.
2004;84:579e621.
16. Kaplanski G, Marin V, Fabrigoule M, et al. Thrombin-activated
human endothelial cells support monocyte adhesion in vitro
following expression of intercellular adhesion molecule-1
(ICAM-1; CD54) and vascular cell adhesion molecule-1
(VCAM-1; CD106). Blood. 1998;92:1259e1267.
17. Mosnier LO, Sinha RK, Burnier L, Bouwens EA, Griffin JH.
Biased agonism of protease-activated receptor 1 by activated
protein C caused by noncanonical cleavage at Arg46. Blood.
2012;120:5237e5246.
18. Finigan JH, Dudek SM, Singleton PA, et al. Activated protein C
mediates novel lung endothelial barrier enhancement. J Biol
Chem. 2005;280:17286e17293.
19. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene
expression profile of antithrombotic protein c defines new
mechanisms modulating inflammation and apoptosis. J Biol
Chem. 2001;276:11199e11203.
20. Kuriyama N, Isaji S, Hamada T, et al. The cytoprotective
effects of addition of activated protein C into preservation
solution on small-for-size grafts in rats. Liver Transpl.
2010;16:1e11.
21. Matsuda A, Kuriyama N, Kato H, et al. Research article
comparative study on the cytoprotective effects of activated
protein C treatment in nonsteatotic and steatotic livers under
ischemia-reperfusion injury. Biomed Res Int. 2015;2015:1e13.
22. Ito T, Kuriyama N, Kato H, et al. Sinusoidal protection by
sphingosine-1-phosphate receptor 1 agonist in liver
ischemia-reperfusion injury. J Surg Res. 2018;222:139e152.
23. Feistritzer C. Endothelial barrier protection by activated
protein C through PAR1-dependent sphingosine 1-phosphate
receptor-1 crossactivation. Blood. 2005;105:3178e3184.
24. Ludeman MJ, Kataoka H, Srinivasan Y, Esmon NL, Esmon CT,
Coughlin SR. PAR1 cleavage and signaling in response to
activated protein C and thrombin. J Biol Chem.
2005;280:13122e13128.
25. White LE, Hassoun HT. Inflammatory mechanisms of organ
crosstalk during ischemic acute kidney injury. Int J Nephrol.
2012;2012:505197.
26. Chong AJ, Pohlman TH, Hampton CR, Shimamoto A,
Mackman N, Verrier ED. Tissue factor and thrombin mediate
myocardial ischemia-reperfusion injury. Ann Thorac Surg.
2003;75:S649eS655.
27. Rajput PS, Lyden PD, Chen B, et al. Protease activated
receptor-1 mediates cytotoxicity during ischemia using
in vivo and in vitro models. Neuroscience. 2014;281:229e240.
28. Eter El EA, Aldrees A. Inhibition of proinflammatory cytokines
by SCH79797, a selective protease-activated receptor 1
antagonist, protects rat kidney against ischemia-reperfusion
injury. Shock. 2012;37:639e644.
29. Strande JL, Hsu A, Su J, Fu X, Gross GJ, Baker JE. SCH 79797, a
selective PAR1 antagonist, limits myocardial ischemia/
reperfusion injury in rat hearts. Basic Res Cardiol.
2007;102:350e358.
30. Wang J, Jin H, Hua Y, Keep RF, Xi G. Role of protease-activated
receptor-1 in brain injury after experimental global cerebral
ischemia. Stroke. 2012;43:2476e2482.
31. Jose´ RJ, Williams AE, Mercer PF, Sulikowski MG, Brown JS,
Chambers RC. Regulation of neutrophilic inflammation by
proteinase-activated receptor 1 during bacterial pulmonary
infection. J Immunol. 2015;194:6024e6034.
32. Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a
novel, orally active himbacine-based thrombin receptor
ARTICLEI
NPRESS
16
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
j o u r n a l o f s u r g i c a l r e s e a r c h - 2 0 1 9 ( - ) 1 e1 6
antagonist (SCH 530348) with potent antiplatelet activity. J
Med Chem. 2008;51:3061e3064.
Hamada T, Fondevila C, Busuttil RW, Coito AJ.
Metalloproteinase-9 deficiency protects against hepatic
ischemia/reperfusion injury. Hepatology. 2007;47:186e198.
Suzuki S, Toledo-Pereyra LH, Rodriguez FJ, Cejalvo D.
Neutrophil infiltration as an important factor in liver
ischemia and reperfusion injury. Modulating effects of FK506
and cyclosporine. Transplantation. 1993;55:1265e1272.
Duarte S, Hamada T, Kuriyama N, Busuttil RW, Coito AJ.
TIMP-1 deficiency leads to lethal partial hepatic ischemia and
reperfusion injury. Hepatology. 2012;56:1074e1085.
Wei R, Zhang R, Xie Y, Shen L, Chen F. Hydrogen suppresses
hypoxia/reoxygenation-induced cell death in hippocampal
neurons through reducing oxidative stress. Cell Physiol
Biochem. 2015;36:585e598.
Xie F, Li Z-P, Wang H-W, et al. Evaluation of liver ischemiareperfusion injury in rabbits using a nanoscale ultrasound
contrast agent targeting ICAM-1. PLoS One. 2016;11:e0153805.
Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R.
Proteinase-activated receptors. Pharmacol Rev.
2001;53:245e282.
Vergnolle N. Modulation of visceral pain and inflammation by
protease-activated receptors. Br J Pharmacol.
2004;141:1264e1274.
Tsuboi H, Naito Y, Katada K, et al. Role of the thrombin/
protease-activated receptor 1 pathway in intestinal ischemiareperfusion injury in rats. Am J Physiol Gastrointest Liver
Physiol. 2007;292:G678eG683.
Rezaie A. Protease-activated receptor signalling by
coagulation proteases in endothelial cells. Thromb Haemost.
2017;112:876e882.
Marra F, DeFranco R, Grappone C, et al. Expression of the
thrombin receptor in human liver: up-regulation during acute
and chronic injury. Hepatology. 1998;27:462e471.
Rullier A, Senant N, Kisiel W, et al. Expression of proteaseactivated receptors and tissue factor in human liver. Virchows
Arch. 2005;448:46e51.
Dupuy E, Hainaud P, Villemain A, et al. Tumoral angiogenesis
and tissue factor expression during hepatocellular carcinoma
progression in a transgenic mouse model. J Hepatol.
2003;38:793e802.
Kohli V, Selzner M, Madden JF, Bentley RC, Clavien P-A.
Endothelial cell and hepatocyte deaths occur by apoptosis
after ischemia-reperfusion injury in the rat liver.
Transplantation. 1999;67:1099e1105.
Natori S, Selzner M, Valentino KL, et al. Apoptosis of
sinusoidal endothelial cells occurs during liver preservation
injury by a caspase-dependent mechanism. Transplantation.
1999;68:89e96.
Yufu T, Hirano K, Bi D, et al. Rac1 regulation of surface
expression of protease-activated receptor-1 and
responsiveness to thrombin in vascular smooth muscle cells.
Arterioscler Thromb Vasc Biol. 2005;25:1506e1511.
Yokomori H, Oda M, Yoshimura K, et al. Caveolin-1 and rac
regulate endothelial capillary-like tubular formation and
fenestral contraction in sinusoidal endothelial cells. Liver Int.
2009;29:266e276.
Flynn AN, Buret AG. Proteinase-activated receptor 1 (PAR-1)
and cell apoptosis. Apoptosis. 2004;9:729e737.
Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical
pathways of caspase activation during apoptosis. Annu Rev
Cell Dev Biol. 1999;15:269e290.
51. Salvesen GS, Abrams JM. Caspase activation e stepping on
the gas or releasing the brakes? Lessons from humans and
flies. Oncogene. 2004;23:2774e2784.
52. Kim HN, Kim YR, Ahn SM, Lee SK, Shin HK, Choi BT. Protease
activated receptor-1 antagonist ameliorates the clinical
symptoms of experimental autoimmune encephalomyelitis
via inhibiting breakdown of blood-brain barrier. J Neurochem.
2015;135:577e588.
53. Nowatari T, Murata S, Nakayama K, et al. Sphingosine 1phosphate has anti-apoptotic effect on liver sinusoidal
endothelial cells and proliferative effect on hepatocytes in a
paracrine manner in human. Hepatol Res. 2014;45:1136e1145.
54. Cantley LC. The phosphoinositide 3-kinase pathway. Science.
2002;296:1655e1657.
55. Zhang R, Zhang L, Manaenko A, Ye Z, Liu W, Sun X. Helium
preconditioning protects mouse liver against ischemia and
reperfusion injury through the PI3K/Akt pathway. J Hepatol.
2014;61:1048e1055.
56. Lu Z, Xu S. ERK1/2 MAP kinases in cell survival and apoptosis.
IUBMB Life. 2006;58:621e631.
57. Yang J-Y, Michod D, Walicki J, Widmann C. Surviving the kiss
of death. Biochem Pharmacol. 2004;68:1027e1031.
58. Perkins D, Pereira EFR, Aurelian L. The herpes simplex
virus type 2 R1 protein kinase (ICP10 PK) functions as a
dominant regulator of apoptosis in hippocampal neurons
involving activation of the ERK survival pathway and
upregulation of the antiapoptotic protein Bag-1. J Virol.
2003;77:1292e1305.
59. Yang J-N, Chen J, Xiao M. A protease-activated receptor 1
antagonist protects against global cerebral ischemia/
reperfusion injury after asphyxial cardiac arrest in rabbits.
Neural Regen Res. 2017;12:242e248.
60. Thomas CJ, Lim NR, Kedikaetswe A, et al. Evidence that the
MEK/ERK but not the PI3K/Akt pathway is required for
protection from myocardial ischemiaereperfusion injury by
30 ,40 -dihydroxyflavonol. Eur J Pharmacol. 2015;758:53e59.
61. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase
signalling: taking a RISK for cardioprotection. Heart Fail Rev.
2007;12:217e234.
62. Allan LA, Morrice N, Brady S, Magee G, Pathak S, Clarke PR.
Inhibition of caspase-9 through phosphorylation at Thr 125
by ERK MAPK. Nat Cell Biol. 2003;5:647e654.
63. Segarra J, Balenci L, Drenth T, Maina F, Lamballe F. Combined
signaling through ERK, PI3K/AKT, and RAC1/p38 is required
for met-triggered cortical neuron migration. J Biol Chem.
2006;281:4771e4778.
64. Zhou J, Du T, Li B, Rong Y, Verkhratsky A, Peng L. Crosstalk
between MAPK/ERK and PI3K/AKT signal pathways during
brain ischemia/reperfusion. ASN Neuro. 2015;7,
175909141560246.
65. Wang H, Ubl JJ, Stricker R, Reiser G. Thrombin (PAR-1)induced proliferation in astrocytes via MAPK involves
multiple signaling pathways. Am J Physiol Cell Physiol.
2002;283:C1351eC1364.
66. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the
secondary prevention of atherothrombotic events. N Engl J
Med. 2012;366:1404e1413.
67. David AM, Benjamin MS, Keith AAF, et al. Evaluation of a
novel antiplatelet agent for secondary prevention in patients
with a history of atherosclerotic disease: design and rationale
for the thrombin-receptor antagonist in secondary
prevention of atherothrombotic ischemic events (TRA 2 P)TIMI 50 trial. Am Heart J. 2009;158:335e341.e3.
...
論文の公開元へ
